Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21737579 | 0.82 | GAA (0.44) | GAAALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL19556424 | 0.79 | KDM4E (0.41) | GAAALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL12156243 | 0.79 | GAA (0.56) | GAAALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL12788582 | 0.79 | GAA (0.56) | GAAALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL12846945 | 0.79 | GAA (0.70) | GAAALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL20037038 | 0.79 | GAA (0.70) | GAAALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL13683148 | 0.78 | GAA (0.44) | GAAALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL16200267 | 0.76 | GAA (0.38) | GAAALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL20037056 | 0.76 | GAA (0.60) | GAAALDH1A1TSHRHSD17B10LMNA | |
| SCHEMBL21719809 | 0.75 | CYP2C19 (0.45) | GAAALDH1A1TSHRHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1928236-B1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC (BM) | 2011-11-23 | — | — | EP | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20110059953-A1 | COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS | MEDICAL RESEARCH COUNCIL (GB) | 2011-03-10 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-6936630-B2 | Substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040127526-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2004-07-01 | — | — | US | disclosed |
| US-6686476-B2 | ANTICHOILESTEROL AGENTS; CARDIOVASCULAR DISORDERS | WYETH | 2004-02-03 | — | — | US | disclosed |
| US-20030013747-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | WYETH | 2003-01-16 | — | — | US | disclosed |
| US-6455566-B1 | Substituted 1-aryl-3-heteroaryl-thioureas (or isothioureas) as antiatherosclerotic agents | WYETH | 2002-09-24 | — | — | US | disclosed |
| WO-1999011638-A1 | SUBSTITUTED 1-ARYL-3- HETEROARYL-THIOUREAS AND SUBSTITUTED 1-ARYL-3-HETEROARYL-ISOTHIOUREAS AS ANTIATHEROSCLEROTIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | SQOR, ATG4A, NQO1 | GAA 236/4885ALDH1A1 746/4885TSHR 4864/4885 |
| US-20030013747-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | CBR1, LDLR, HMGCR | GAA 3175/4885ALDH1A1 740/4885TSHR 406/4885 |
| US-20040127526-A1 | Novel substituted 1-aryl-3-heteroaryl-thioureas and substituted 1-aryl-3-heteroaryl-isothioureas as antiatherosclerotic agents | CBR1, LDLR, HMGCR | GAA 3175/4885ALDH1A1 740/4885TSHR 406/4885 |
| US-20110059953-A1 | COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS | TP53, TP53BP1, MDM2 | GAA 4749/4885ALDH1A1 3561/4885TSHR 942/4885 |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | GAA 3290/4885ALDH1A1 2505/4885TSHR 4735/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | GAA 185/4885ALDH1A1 2142/4885TSHR 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.